Polaris Pharmaceuticals
Pharmaceuticals, Dual Company Headquarters, San Diego, California, United States, 11-50 Employees
Phone Number: 88**********
Who is POLARIS PHARMACEUTICALS
Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases ...
Read More
-
Headquarters: Dual Company Headquarters, San Diego, California, United States
-
Date Founded: 2006
-
Employees: 11-50
-
Revenue: $1 Billion and Over
-
Active Tech Stack: See technologies
-
CEO:
Shaw Chen
Email
Phone
Industry: Pharmaceuticals
SIC Code: 2835
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from POLARIS PHARMACEUTICALS
Polaris Pharmaceuticals Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Polaris Pharmaceuticals
Answer: Polaris Pharmaceuticals's headquarters are located at Dual Company Headquarters, San Diego, California, United States
Answer: Polaris Pharmaceuticals's phone number is 88**********
Answer: Polaris Pharmaceuticals's official website is https://polarispharma.com
Answer: Polaris Pharmaceuticals's revenue is $1 Billion and Over
Answer: Polaris Pharmaceuticals's SIC: 2835
Answer: Polaris Pharmaceuticals's NAICS: 325412
Answer: Polaris Pharmaceuticals has 11-50 employees
Answer: Polaris Pharmaceuticals is in Pharmaceuticals
Answer: Polaris Pharmaceuticals contact info: Phone number: 88********** Website: https://polarispharma.com
Answer: Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans. Polaris' lead project is ADI-PEG 20, a biotherapeutic agent that is in advanced clinical development for the treatment of hepatocellular carcinoma and metastatic melanoma. Polaris is collaborating with EnzymeRx in the development of Uricase-PEG 20 for the treatment of gout, tumor lysis syndrome, and other diseases related to hyperuricemia. Polaris is also researching and developing other biotherapeutic agents and has a small molecule drug program. The latter utilizes a rational structure-based approach for the design of novel compounds that inhibit the biological function of cancer-related protein targets.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month